Inhibition of the TIRAP-c-Jun interaction as a therapeutic strategy for AP1-mediated inflammatory responses

Int Immunopharmacol. 2019 Jun:71:188-197. doi: 10.1016/j.intimp.2019.03.031. Epub 2019 Mar 22.

Abstract

Bacterial endotoxin-induced sepsis causes 30-40% of the deaths in the intensive care unit (ICU) globally, for which there is no pharmacotherapy. Lipopolysaccharide (LPS), a bacterial endotoxin, stimulates the Toll-like receptor (TLR)-4 signalling pathways to upregulate the expression of various inflammatory mediators. Here, we show that the TIRAP and c-Jun protein signalling complex forms in macrophages in response to LPS stimulation, which increases the AP1 transcriptional activity, thereby amplifying the expression of inflammatory mediators. Using a computer-aided molecular docking platform, we identified gefitinib as a putative inhibitor of the TIRAP-c-Jun signalling complex. Further, we demonstrated the ability of gefitinib to inhibit the interaction of TIRAP-c-Jun with in vitro experiments and with a mouse model of sepsis. Importantly, pre-treatment with gefitinib increased the survival of the mice that received a lethal dose of LPS compared to that of the controls. These findings verify the ability of gefitinib to directly disrupt the interaction of TIRAP and c-Jun, thereby inhibiting a major inflammatory response that is often observed in patients experiencing sepsis.

Keywords: Activator protein-1 (AP-1); Inflammation; Macrophage; Proinflammatory cytokines; TIRAP; c-Jun.

MeSH terms

  • Animals
  • Cells, Cultured
  • Disease Models, Animal
  • Gefitinib / pharmacology*
  • Gefitinib / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Inflammation / metabolism
  • Lipopolysaccharides / immunology
  • Macrophages / physiology*
  • Male
  • Membrane Glycoproteins / antagonists & inhibitors*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Molecular Docking Simulation
  • Molecular Targeted Therapy
  • Protein Binding / drug effects
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-jun / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-jun / metabolism
  • Receptors, Interleukin-1 / antagonists & inhibitors*
  • Receptors, Interleukin-1 / metabolism
  • Sepsis / drug therapy*
  • Sepsis / immunology
  • Sepsis / metabolism
  • Signal Transduction
  • Toll-Like Receptor 4 / metabolism
  • Transcription Factor AP-1 / genetics
  • Transcription Factor AP-1 / metabolism

Substances

  • Lipopolysaccharides
  • Membrane Glycoproteins
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-jun
  • Receptors, Interleukin-1
  • TIRAP protein, mouse
  • Toll-Like Receptor 4
  • Transcription Factor AP-1
  • Gefitinib